Immunovant, Inc. income statement IMVT

Annual Quarterly

It recorded a net loss of $505.6 million. Diluted earnings per share were -$2.77.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2027 Jun 30, 2026	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2020 Mar 31, 2021	FY 2019 Mar 31, 2020
Research and development	—	—	—	—	—	102	69 +43.1%	48
Selling, general and administrative	68 -19.6%	76 -1.3%	77 +34.8%	57 +19.3%	48 -11.4%	54	40 +117.7%	18
Pretax income	-539 -20.9%	-505 -22.4%	-413 -59.6%	-259 -22.7%	-211 -34.5%	-157	-108 -62.6%	-66
Income tax	-1 -140.4%	0 -75.9%	1 +57.1%	1 +6200.0%	0 +110.7%	-0	-0 -469.1%	0
Net income	-538 -20.3%	-506 -22.2%	-414 -59.6%	-259 -22.9%	-211 -34.6%	-157	-107 -61.8%	-66
Basic EPS	-2.82 +0.6%	-2.77 -1.5%	-2.73 -45.2%	-1.88 -9.9%	-1.71 -19.6%	-1.43	—	—
Diluted EPS	-2.82 +0.6%	-2.77 -1.5%	-2.73 -45.2%	-1.88 -9.9%	-1.71 -19.6%	-1.43	—	—
Weighted average shares, basic	191 +21.1%	182 +20.4%	152 +9.8%	138 +12.2%	123 +12.2%	110	—	—
Weighted average shares, diluted	191 +21.1%	182 +20.4%	152 +9.8%	138 +12.2%	123 +12.2%	110	—	—
Other measures
Depreciation and amortization	0 -2.5%	0 +8.5%	0 +63.2%	0 +19.7%	0 +53.2%	0	0 +209.5%	0

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: IMVT (Nasdaq)
Fiscal year ends: March 31
Incorporated in: DE
Headquarters: Durham, NC
SEC filer status: Large accelerated filer
SEC CIK: 1764013
Former names: Health Sciences Acquisitions Corp (until Dec 20, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.